×

Teva Performance Tough Pill to Swallow

What’s wrong with Teva Pharmaceutical?

Cramer has been endorsing it repeatedly since April 7. Despite Teva's massive generics business, though, and a branded franchise that includes Copaxone, its $3 billion leading treatment for multiple sclerosis, the stock has continued to underperform.

Cramer needed to figure out if the market misunderstood Teva or he did. The company’s North American CEO, Bill Marth, appeared on “Mad Money” to answer his questions. Watch the video to see the full interview.

When this story published, Cramer's charitable trust owned Teva Pharmaceutical.

Call Cramer: 1-800-743-CNBC

Questions for Cramer? madmoney@cnbc.com

Questions, comments, suggestions for the Mad Money website? madcap@cnbc.com